SLS

Sellas Life Sciences Group Inc

NASDAQ: SLS · HEALTHCARE · BIOTECHNOLOGY

$5.25

+10.38% today

Updated 2026-06-04

Market cap

$1.52B

P/E ratio

—

P/S ratio

26.90x

EPS (TTM)

$-0.23

Dividend yield

—

52W range

$1 – $10

Volume

7.6M

Market cap

$1.52B

P/E ratio

—

P/S ratio

26.90x

EPS (TTM)

$-0.23

Dividend yield

—

52W range

$1 – $10

Volume

7.6M

Sellas Life Sciences Group Inc (SLS) Financial Forecast & Price Target 2030

Research-backed projections from analyst consensus, management guidance, and sector analysis.

SLS · Sellas Life Sciences Group Inc · Price target summary

Current

$5.25

Consensus

$10.00

+90.48%

2030 Target

$8.92

+69.90%

DCF

—

Current price

$5.25

Analyst consensus

$10.00

+90.48%

2030 Target

$8.92

+69.90%

Intrinsic (DCF)

—

3 analysts:

1 Buy0 Hold1 Sell

Management guidance

No specific revenue guidance provided by management. CEO Angelos Stergiou is focused on clinical milestone execution (Phase 3 REGAL trial readout imminent at 78/80 events) and advancement of SLS009 pipeline. Company emphasizes sufficient cash runway ($107.1M as of Q1 2026, plus $150M ATM facility) to support operations through at least 12 months.

Sources: Management guidance, analyst consensus, sector analysishigh confidence

SLS · Sellas Life Sciences Group Inc · Revenue & price projection · 2023–2030E

Actual revenue Projected revenue Base case Bull to bear range

Bear case (2030)

$5.25

$0.3B Rev × 3x P/S

Base case (2030)

$8.92

$0.3B Rev × 5x P/S

Bull case (2030)

$14.70

$0.3B Rev × 8x P/S

WallStSmart.com

Financial forecast — research-backed

Metric	2025	2026 (E)	2027 (E)	2028 (E)	2029 (E)	2030 (E)
Revenue	$0.0B	$0.0B	$0.0B	$0.1B	$0.2B	$0.3B
Revenue growth	—	—	104.1%	112.6%	94.7%	72.9%
EPS	$-0.25	$-0.20	$-0.25	$-0.15	$0.05	$0.25
P/S ratio	—	5.0x	5.0x	5.0x	5.0x	5.0x
Implied price	—	$0.53	$1.05	$2.63	$5.25	$8.92

SLS · Sellas Life Sciences Group Inc · Catalysts & risks

Growth catalysts

+ Phase 3 REGAL trial topline readout (78 of 80 events recorded as of Q1 2026 — imminent)

+ SLS009 Phase 2 data readout for newly diagnosed first-line AML (2026-2027)

+ Potential FDA Breakthrough Therapy or Accelerated Approval designation for GPS or SLS009

+ Commercial launch of GPS and/or SLS009 if Phase 3 REGAL succeeds (2027-2028 timeframe)

Key risks

- Phase 3 REGAL trial could fail or show insufficient efficacy — would eliminate GPS value

- SLS009 development delays or negative Phase 2 data

- Limited analyst coverage (3 analysts) and significant short interest (31.1% of float) — elevated volatility risk

- Pre-revenue clinical-stage biotech — no current product revenue; all value contingent on trial success

- Dilution risk from ATM offering ($150M facility) and existing warrant overhang

Methodology

Sellas Life Sciences Group Inc's forward estimates are derived from AI-powered research synthesis combining analyst consensus from 3 Wall Street analysts, management guidance from the latest earnings call, and sector growth forecasts from industry research. Revenue and EPS projections use analyst consensus where available and conservative extrapolation with growth deceleration for outer years. Price targets are calculated using a tiered Price-to-Sales (P/S) methodology, where the P/S multiple is determined by the projected revenue growth rate.

WallStSmart proprietary research model · Not financial advice · Past performance is not indicative of future results · Last researched: May 16, 2026.